Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations

Lieke Mous, Stelly Ballet, Sylvain Dureau, Camille Benoist, Eleonore Frouin, Victor Renault, Laura Kirton, Peter Peneder, Nina Jehanno, Anja L. Frei, Stéphanie Reynaud, Eve Lapouble, Anne-Sophie Plissonnier, Marie-Emmanuelle Legrier, Ellen Blanc, Aurélie Guinot, Jennifer Anderton, Piers Gaunt, Abigail Evans, Sandra J. Strauss, Manuela Krumbholz, Markus Metzler, Elizabeth A. Roundhill, Susan A. Burchill, Samuel Abbou, Sarah Winter, Martin G. McCabe, Nathalie Gaspar, Birgit Geoerger, Gudrun Schleiermacher, Eleni M. Tomazou, Nadège Corradini, Valerie Laurence, Bernadette Brennan, Perrine Marec-Berard, Olivier Delattre, Gaelle Pierron, Didier Surdez

Open source

DOI: 10.1200/jco-26-00280
Published: 2026-11-04
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-26-00280,
  title = {Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With
                    <i>TP53</i>
                    ,
                    <i>STAG2</i>
                    , and
                    <i>CDKN2A</i>
                    Alterations},
  author = {Lieke Mous and Stelly Ballet and Sylvain Dureau and Camille Benoist and Eleonore Frouin and Victor Renault and Laura Kirton and Peter Peneder and Nina Jehanno and Anja L. Frei and Stéphanie Reynaud and Eve Lapouble and Anne-Sophie Plissonnier and Marie-Emmanuelle Legrier and Ellen Blanc and Aurélie Guinot and Jennifer Anderton and Piers Gaunt and Abigail Evans and Sandra J. Strauss and Manuela Krumbholz and Markus Metzler and Elizabeth A. Roundhill and Susan A. Burchill and Samuel Abbou and Sarah Winter and Martin G. McCabe and Nathalie Gaspar and Birgit Geoerger and Gudrun Schleiermacher and Eleni M. Tomazou and Nadège Corradini and Valerie Laurence and Bernadette Brennan and Perrine Marec-Berard and Olivier Delattre and Gaelle Pierron and Didier Surdez},
  year = {2026},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco-26-00280},
  url = {https://doi.org/10.1200/jco-26-00280}
}

RIS

TY  - JOUR
TI  - Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With
                    <i>TP53</i>
                    ,
                    <i>STAG2</i>
                    , and
                    <i>CDKN2A</i>
                    Alterations
AU  - Lieke Mous
AU  - Stelly Ballet
AU  - Sylvain Dureau
AU  - Camille Benoist
AU  - Eleonore Frouin
AU  - Victor Renault
AU  - Laura Kirton
AU  - Peter Peneder
AU  - Nina Jehanno
AU  - Anja L. Frei
AU  - Stéphanie Reynaud
AU  - Eve Lapouble
AU  - Anne-Sophie Plissonnier
AU  - Marie-Emmanuelle Legrier
AU  - Ellen Blanc
AU  - Aurélie Guinot
AU  - Jennifer Anderton
AU  - Piers Gaunt
AU  - Abigail Evans
AU  - Sandra J. Strauss
AU  - Manuela Krumbholz
AU  - Markus Metzler
AU  - Elizabeth A. Roundhill
AU  - Susan A. Burchill
AU  - Samuel Abbou
AU  - Sarah Winter
AU  - Martin G. McCabe
AU  - Nathalie Gaspar
AU  - Birgit Geoerger
AU  - Gudrun Schleiermacher
AU  - Eleni M. Tomazou
AU  - Nadège Corradini
AU  - Valerie Laurence
AU  - Bernadette Brennan
AU  - Perrine Marec-Berard
AU  - Olivier Delattre
AU  - Gaelle Pierron
AU  - Didier Surdez
PY  - 2026
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-26-00280
UR  - https://doi.org/10.1200/jco-26-00280
ER  -

APA

Mous, L., Ballet, S., Dureau, S., Benoist, C., Frouin, E., Renault, V., Kirton, L., Peneder, P., Jehanno, N., Frei, A. L., Reynaud, S., Lapouble, E., Plissonnier, A., Legrier, M., Blanc, E., Guinot, A., Anderton, J., Gaunt, P., Evans, A., Strauss, S. J., Krumbholz, M., Metzler, M., Roundhill, E. A., Burchill, S. A., Abbou, S., Winter, S., McCabe, M. G., Gaspar, N., Geoerger, B., Schleiermacher, G., Tomazou, E. M., Corradini, N., Laurence, V., Brennan, B., Marec-Berard, P., Delattre, O., Pierron, G., & Surdez, D. (2026). Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00280

Source records

crossref · retrieved 2026-11-06T03:19:22.712Z

Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With <i>TP53</i> , <i>STAG2</i> , and <i>CDKN2A</i> Alterations

Credibility signals

Cite this work

BibTeX

RIS

APA

Source records